LCD | Jotup

Whirlpool Corporation Invites You to Experience Real Life at Home at KBIS 2024

Retrieved on:

Tuesday, February 20, 2024

BENTON HARBOR, Mich., Feb. 20, 2024 /PRNewswire/ -- Life at home can be messy, busy and wonderfully unpredictable. Whirlpool Corporation, a leading global major appliance company, understands the beauty of real life, and will showcase innovations designed to suit the needs of real homeowners at the Kitchen & Bath Industry Show (KBIS) on February 27-29, 2024, in the Las Vegas Convention Center. The company's booth will be a celebration of the diverse and dynamic nature of daily life and will demonstrate how its extensive portfolio of brands delivers products that improve life at home – today, tomorrow, and every day.

Key Points:

Whirlpool Corporation, a leading global major appliance company, understands the beauty of real life, and will showcase innovations designed to suit the needs of real homeowners at the Kitchen & Bath Industry Show (KBIS) on February 27-29, 2024, in the Las Vegas Convention Center.
In booth #W2201, attendees can explore products across Whirlpool Corporation's family of brands – Whirlpool, Maytag, KitchenAid, JennAir, Gladiator, and InSinkErator.
"As a company deeply rooted in the fabric of American households, Whirlpool Corporation understands that life isn't always picture-perfect," said Rob Byrd, General Manager, Builder & Pro Sales at Whirlpool Corporation.
Exclusive to Whirlpool Corporation, this innovative feature makes tackling tough messes a breeze and requires just water, not harsh cleaners.

Global Digital Signage Market to Reach $44.72 Billion by 2030 Owing To Increasing Demand for Digital Advertising | Says Coherent Market Insights

Retrieved on:

Tuesday, February 20, 2024

Additionally, the cost-effectiveness and flexibility offered by digital signage compared to traditional advertising methods have also contributed to its growing popularity.

Key Points:

Additionally, the cost-effectiveness and flexibility offered by digital signage compared to traditional advertising methods have also contributed to its growing popularity.
AI-powered digital signage systems can analyze audience demographics and behavior, enabling advertisers to deliver personalized and targeted content.
Interactive Digital Signage: The increasing trend of interactive digital signage is another significant development in the market.
Video screens, digital posters, kiosks, and other types of digital signage solutions are also gaining traction in the market.

Global Digital Signage Market to Reach $44.72 Billion by 2030 Owing To Increasing Demand for Digital Advertising | Says Coherent Market Insights

Retrieved on:

Tuesday, February 20, 2024

Additionally, the cost-effectiveness and flexibility offered by digital signage compared to traditional advertising methods have also contributed to its growing popularity.

Key Points:

Additionally, the cost-effectiveness and flexibility offered by digital signage compared to traditional advertising methods have also contributed to its growing popularity.
AI-powered digital signage systems can analyze audience demographics and behavior, enabling advertisers to deliver personalized and targeted content.
Interactive Digital Signage: The increasing trend of interactive digital signage is another significant development in the market.
Video screens, digital posters, kiosks, and other types of digital signage solutions are also gaining traction in the market.

Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024

Retrieved on:

Thursday, February 15, 2024

Community health, Form 1095, AstraZeneca, ICR, CMS, Food, Growth, NGS, Risk, Risk assessment, Food and Drug Administration, Patient, Journal, Kidney disease, Kidney, LCD, Prescription, Research, Pharmaceutical industry

LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease, today reported financial results for the fiscal second quarter ended December 31, 2023.

Key Points:

LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease, today reported financial results for the fiscal second quarter ended December 31, 2023.
The Company plans to issue another announcement following today’s report of financial results regarding the date and time of its conference call and webcast to discuss second quarter financial results and other key events.
Total billable volume of 734 tests during the second quarter (representing 69% of all tests in the period, including non-billable study tests).
Operating cost reductions commenced during the fiscal second quarter continued with a fiscal third quarter cash burn target approximately 33% less than in the prior quarter and approximately 50% less than in the first quarter of fiscal 2024.

Casio to Celebrate 50th Watch Anniversary with Commemorative Timepiece

Retrieved on:

Thursday, February 15, 2024

LCD, Smartphone, STN, Television

TOKYO, Feb. 15, 2024 /PRNewswire/ -- Casio Computer Co., Ltd. announced today the release of a new watch re-creating the Casiotron QW02, the world's first line of digital watches with an automatic calendar function, to commemorate the 50th anniversary of Casio watches. The new TRN-50 is available in a limited edition of 4,000 watches worldwide.

Key Points:

TOKYO, Feb. 15, 2024 /PRNewswire/ -- Casio Computer Co., Ltd. announced today the release of a new watch re-creating the Casiotron QW02, the world's first line of digital watches with an automatic calendar function, to commemorate the 50th anniversary of Casio watches.
Casio originally released the Casiotron in 1974, breaking ground with a digital wristwatch inspired by the insight that "watches simply add up seconds."
The watch made the most of the original digital technologies Casio had developed in its calculator business, bringing the concept of a fully automatic wristwatch to life.
The original watch exterior, including its size, is meticulously re-created in a design that meets present-day quality standards.

Corsair Gaming Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on:

Tuesday, February 13, 2024

Corsair Gaming, Inc. (Nasdaq: CRSR) (“Corsair” or the “Company”), a leading global provider and innovator of high-performance products for gamers, streamers, content-creators, and gaming PC builders, today announced financial results for the fourth quarter and full year ended December 31, 2023, as well as guidance for 2024.

Key Points:

Corsair Gaming, Inc. (Nasdaq: CRSR) (“Corsair” or the “Company”), a leading global provider and innovator of high-performance products for gamers, streamers, content-creators, and gaming PC builders, today announced financial results for the fourth quarter and full year ended December 31, 2023, as well as guidance for 2024.
Net revenue was $417.3 million compared to $363.2 million in the third quarter of 2023 and $398.7 million in the fourth quarter of 2022.
Adjusted EBITDA was $33.7 million, compared to $23.0 million in the third quarter of 2023, and $32.0 million in the fourth quarter of 2022.
Corsair will host a conference call to discuss the fourth quarter and full year 2023 financial results today at 2:00 p.m. Pacific Time.

General Micro Systems’ Lightweight Smart Rugged Tablet/Display Adds Unmatched Flexibility, Portability and Intelligence to the Battlefield

Retrieved on:

Tuesday, February 13, 2024

WEST 2024 – General Micro Systems (GMS) will showcase its highly flexible, lightweight portable and intelligent X9 Spider Rugged Thunderbolt™ 4 Tablet/Display this week at the West 2024 Conference.

Key Points:

WEST 2024 – General Micro Systems (GMS) will showcase its highly flexible, lightweight portable and intelligent X9 Spider Rugged Thunderbolt™ 4 Tablet/Display this week at the West 2024 Conference.
The X9 Spider Rugged Thunderbolt Tablet/Display introduced today offers these same capabilities but adds the mobile phone ARM®-based Qualcomm QRB6165 mobile processor for generative AI, inference tracking, extreme vector graphics and image processing/enhancement.
“By adding the impressive capabilities of the Qualcomm AI processor, the X9 Spider Rugged Thunderbolt tablet and display becomes a smart, lightweight, flexible tablet like no other on the battlefield.
“Cool to the touch, rugged, thin, wireless and lightweight, never before has such a dual-mode smart tablet/display been available.

Medicare Coverage Significantly Expanded for the Eversense E3 CGM System

Retrieved on:

Monday, February 12, 2024

Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal only patients, by the first three Medicare Administrative Contractors (MACs).

Key Points:

Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal only patients, by the first three Medicare Administrative Contractors (MACs).
Medicare coverage has been expanded for implantable CGMs to include all people with diabetes using insulin, removing the previous requirement for multiple insulin administrations per day.
Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense E3 CGM System can sign up at https://www.ascensiadiabetes.com/eversense/become-a-provider/ .
Ascensia Diabetes Care, the maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, is a PHC Holdings Corporation (TSE: 6523) company.

MEDICARE COVERAGE SIGNIFICANTLY EXPANDED FOR THE EVERSENSE E3 CGM SYSTEM

Retrieved on:

Monday, February 12, 2024

Blood glucose monitoring, MAC, Diabetes, CGM, Macs, Himawari (satellites), NGS, Practitioner, History, Patient, Policy, Insulin, LCD, Physician, BGM, Pharmaceutical industry

PARSIPPANY, N.J., Feb. 12, 2024 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal only patients, by the first three Medicare Administrative Contractors (MACs).

Key Points:

Medicare coverage has been expanded for implantable CGMs to include all people with diabetes using insulin, removing the previous requirement for multiple insulin administrations per day.
Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense E3 CGM System can sign up at https://www.ascensiadiabetes.com/eversense/become-a-provider/ .
Alternatively, contact 1-844-SENSE4U (1-844-736-7348) to learn more about the first and only long-term implantable CGM system.
Ascensia Diabetes Care, the maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, is a PHC Holdings Corporation (TSE: 6523) company.

Kidney Patients Target Medicare Transplant Double Standard

Retrieved on:

Friday, February 9, 2024

WASHINGTON, Feb. 9, 2024 /PRNewswire/ -- Today, the American Association of Kidney Patients (AAKP), the largest and oldest kidney patient organization in the nation, issued an Official Statement (appears below) and an AAKP Closer Look report highlighting a new, double standard and unequal access for Medicare kidney transplant recipients who rely upon molecular blood tests for organ health surveillance and the identification of early organ rejection. Kidney disease and kidney failure disproportionately impact minority Americans. Federal data consistently demonstrates that, among historically disadvantaged communities, there are tremendous barriers and lack of opportunity to receive a kidney transplant and furthermore, re-transplantation when a donor organ fails.

Key Points:

The new restrictions severely limit Medicare patients and transplant professionals from accessing molecular blood tests, covered by Medicare and utilized since 2017.
It is absolutely clear this is a new double standard for Medicare transplant recipients.
Today, Medicare patients with a kidney transplant in South Carolina and across the nation face the new reality of unequal treatment to protect their precious gifts of life.
Their failed leadership has empowered unelected, unaccountable, and faceless for-profit contractors to make life and death decisions that negatively impact kidney transplant patients on Medicare.